Viewing Study NCT01110993


Ignite Creation Date: 2025-12-25 @ 1:09 AM
Ignite Modification Date: 2026-02-22 @ 4:52 PM
Study NCT ID: NCT01110993
Status: COMPLETED
Last Update Posted: 2014-02-03
First Post: 2010-04-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
Sponsor: Merck KGaA, Darmstadt, Germany
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Sclerosis, Relapsing-Remitting View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Multiple Sclerosis, Interferon-beta 1-a View